Jennifer is a leader in our Pharmaceuticals & Medical Products Practice, and she serves pharmaceutical and high growth biotechnology companies on innovation and go-to-market strategies for biological therapeutics and vaccines. A scientist by training, Jennifer leads McKinsey’s knowledge development in vaccines and infectious diseases and is currently a leader of the firm’s public health response to COVID-19.
Jennifer has worked with a broad set of industry-leading biopharmaceutical companies to define their growth strategies with the development and launch of innovative platforms, products, and portfolios in the vaccines and broader biologics markets. She has written and spoken extensively on the topic of vaccines, including sessions at BIO, The Sabin-Aspen Vaccine Science & Policy Group, and the US National Vaccine Advisory Committee. Jennifer has also served clients across the biosimilars industry as it has accelerated in momentum over the past several years.
Prior to joining McKinsey, Jennifer was a trainee at Novartis Institutes for Biomedical Research in their autoimmunity, transplantation, and inflammatory disease area group. She holds a PhD in immunology from Northwestern University and a BS in ecology and evolutionary biology from the University of Arizona, where she also obtained a BA in Spanish.